Including genetic predisposition data in insurance appeals can strengthen the narrative: 'Patient carries multiple variants associated with impaired satiety signaling and metabolic dysregulation despite documented lifestyle efforts.' This shifts the framing from personal responsibility to biology, potentially improving authorization rates
Zepbound is approved for use by adults with obesity, or those who are overweight and also have weight-related medical problems, such as diabetes
Dont forget: Just as these telehealth firms are working it out with Novo on the remix, a whole new pill version of GLP-1s is on the horizonand will likely shake up the weight-loss market once again. LB About the author Lucy Brewster Lucy Brewster reports on all things markets and investing for Brew Markets.
Lower scores are better , thus the authors considered this data as potential evidence supporting slowing of disease progression
Can a telehealth program provide branded Ozempic
never double-dose to make up for a missed injection